Prescribing information



ATECTURA BREEZHALER is indicated as a maintenance treatment for asthma in adults and adolescents 12 years of age and older, not adequately controlled with inhaled corticosteroids and inhaled short-acting beta2-agonists.1



  1. ATECTURA BREEZHALER Summary of Product Characteristics.
Rate this content: 
No votes yet
UK | February 2021 | 103413

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]